throughout biopharmaceutical medicine that not everyone responds in precisely the same way to administration of the same drug, but the magnitude and consequences of individual differences in response are perhaps of particular salience here.)
Before a physician prescribes an analgesic, he or she needs to ask the patient a question whose answer is far less straightforward than one might initially suppose: How much pain are you experiencing? As Joffe and colleagues noted, "To effectively treat pain, it must be detected and quantified using a validated assessment tool." 10 Going a considerable step further, pain assessment becomes even more challenging when an individual who is almost certainly experiencing severe pain is unable to self-report the pain: examples include patients in cardiovascular intensive care units and medical/surgical/ trauma units. 11 Deciding upon the appropriate magnitude of dose and frequency of dosing can therefore be both difficult and vexing: too little too infrequently and a patient can avoidably suffer excruciating pain; too much too often can lead to abuse and addiction, "a chronically relapsing disorder characterized by the compulsive desire to use drugs and a loss of control over consumption." 12 As Garattini observed, "drug authorization, prescription, and utilization are all based on benefit-risk assessment," 13 an axiom exemplified powerfully in this context.
Making meaningful progress in the crusade against the opioid abuse epidemic requires attention to focus first on multiple identifiable components of a potential integrated solution, and then on the multidisciplinary cooperation necessary to design and implement this multifaceted solution. The FDA Opioids Action Plan 14 contains such components and actions, including an explicit desired outcome in each case. The actions are as follows: expand the use of advisory committees, develop warnings and safety information for immediate-release opioid labeling, strengthen postmarket requirements, update Risk Evaluation and Mitigation Strategy programs, expand access to abuse-deterrent formulations to discourage abuse, support better treatment, and reassess the risk-benefit approval framework for opioid use. Examination of the peer-reviewed literature also reveals a rich and diverse collection of papers addressing many topics of relevance: some references are provided for further reading. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] As a concrete example of progress in this area, consider FDA's April 2015 Guidance for Industry entitled "Abusedeterrent Opioids: Evaluation and Labeling," which provided their "current thinking about the studies that should be conducted to demonstrate that a given formulation has abusedeterrent properties." 34 The guidance also contained recommendations about how those studies should be performed and evaluated, and discussed description of the studies and their implications in product labeling. FDA has now approved an array of opioids with labeling describing abuse-deterrent properties consistent with this guidance, including OxyContin, Targiniq ER, Embeda, Hysingla ER, MorphaBond, Xtampza ER, Troxyca ER, Arymo ER, Vantrela ER, and RoxyBond. RoxyBond (oxycodone hydrochloride) was approved on April 20, 2017 , and is the first immediate-release opioid analgesic approved with labeling describing its abuse-deterrent properties consistent with the guidance: based on laboratory studies, "RoxyBond tablets are resistant to certain forms of manipulation such as crushing, grinding, or otherwise extracting oxycodone from the tablet that are typically used to make opioids easier to abuse by the nasal and intravenous routes." 35 In terms of general drug safety, the last decade has seen major systematic advances in the science of drug safety, "the science that supports the medical product safety system at every stage of the product life cycle, from premarket testing and development through postmarketing surveillance and risk management." 36 For many years previously, it tended to be single catastrophic events that catapulted safety considerations to the forefront in various regulatory jurisdictions. The signing into law of the US Federal Food, Drug, and Cosmetics Act of 1938, which revised the Pure Food and Drug Act of 1906 and had been under congressional discussion for several years, was galvanized by the elixir sulfanilamide tragedy in which more than 100 people were fatally poisoned by an ingredient in the elixir following its ingestion. 37 An analogously tragic and influential set of circumstances in Europe concerning the drug thalidomide led to the United Kingdom's Medical Act of 1968. (The US did not experience the same tragedy from the use of thalidomide. Having seen the reports from Europe, Dr Frances Kelsey, a newly appointed reviewer at the FDA, completed considerable research and, as a result, took a firm stance against the drug's approval. This diligence was recognized in 1962 by her receipt of the President's Award for Distinguished Federal Civilian Service.) It can be argued that between 1938 and 2007 in the US there was a lack of forward momentum with regard to drug safety, perhaps in part due to the importance that came to be placed upon drug efficacy as a result of the Kefauver-Harris Amendments to the US Federal Food, Drug, and Cosmetics Act of 1938, which were signed into law by President Kennedy in October 1962 and, for the first time, required the provision of compelling evidence of efficacy when submitting a marketing application. Fortunately, the Food and Drug Administration Amendments Act of 2007 reinvigorated safety considerations.
A detailed account of many relevant events can be found in Turner and Durham, 38 but one quote from a 2008 FDA document seems particularly prescient in the current context. It comes from the FDA's PDUFA IV Drug Safety Five-Year Plan, and reads as follows 39 :
FDAAA recognizes FDA's critical role in assuring the safe and appropriate use of drugs after they are marketed. Congress, consistent with many recommendations made over the past two years by the Institute of Medicine, the [US General Accountability Office], and a multitude of others, confirms that FDA's major responsibility of ensuring that marketed drugs are used as safely and effectively as possible is equally as important as getting new safe and effective drugs to market quickly and efficiently. Congress accomplished this by legislating PDUFA IV and FDAAA, which gave FDA substantial new resources for medical product safety, as well as a variety of regulatory tools and authorities to ensure safe and appropriate use of drugs. With the goal of maintaining a systematic and scientific approach to the evaluation of benefit/risk throughout the product lifecycle, FDA must build the scientific and administrative capacity needed to become active and collaborative players in the US healthcare delivery system. (italic added for emphasis) Various FDA initiatives have embraced persuasion and collaboration as key components of this responsibility. One is the Safe Use Initiative, the goal of which is "to reduce preventable harm by identifying specific, preventable medication risks and developing, implementing and evaluating cross-sector interventions with partners who are committed to safe medication use." 40 Occurrences that lead to preventable harm include prescription errors (eg, inappropriate dose, contraindication issues), and dispensing errors (occurrences such as wrongsite surgeries can be added to a list capturing preventable harms in medicine in general).
Another consideration of relevance here concerns Risk Evaluation and Mitigation Strategy programs that require manufacturers of extended-release/long-acting opioids to fund continuing medical education (CME) providers to offer CME courses on the appropriate use of these products at low or zero cost, subject to an online FDA curriculum. 2 However, Califf and colleagues went a step further, commenting that "although this voluntary training remains an important public health measure, the FDA continues to support mandatory education for prescribers, as called for in the 2011 Prescription Drug Abuse Prevention Plan and reemphasized in the 2014 National Drug Control Strategy. Together with other federal agencies and the clinical community, we should strive to overcome obstacles to enacting this measure." 2 Another important paper was published late last year by Rudd and colleagues. 41 They commented as follows:
A multifaceted, collaborative public health and law enforcement approach is urgently needed. Response efforts include implementing the CDC Guideline for Prescribing Opioids for Chronic Pain, [42] improving access to and use of prescription drug monitoring programs, enhancing naloxone distribution and other harm reduction approaches, increasing opioid use disorder treatment capacity, improving linkage into treatment, and supporting law enforcement strategies to reduce the illicit opioid supply. Baptism by fire indeed: we wish Dr Gottlieb and his Agency colleagues (and other federal and law enforcement agencies and the clinical community) every success in addressing an epidemic that is blighting our country at both the individual and public health levels.
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